이화여자대학교

Kang, Soosung Professor

Pharmaceutical Sciences/Industrial Pharmaceutical Science/Division of Pharmacy

강수성 프로필 사진 
Dr. Kang is engaged in the development of new drugs, employing medicinal chemistry, computational chemistry, and organic chemistry, as a faculty member at the College of Pharmacy, Ewha Womans University. He earned his Ph.D. in Organic Chemistry/Medicinal Chemistry from Purdue University in the United States in 2009, under the guidance of Professor Lipton. Subsequently, until 2014, he served as a research associate at the Silverman group at Northwestern University in the United States, conducting diverse research on central nervous system drug development. From 2014 to 2017, he held the position of principal researcher at the New Drug Development Center, K-Med Hub, contributing to research on treatments for Alzheimer's disease, inflammatory diseases, and anticancer agents. Since March 2017, he has been serving as a professor at his current university.
Currently, his research focuses on the innovative development of therapeutics for neurodegenerative diseases, inflammation, and antibiotics, particularly targeting mitochondrial-involved conditions. He employs tools from medicinal chemistry, organic chemistry, computational chemistry, and chemical biology for this endeavor.
  • Director, Global AI Drug Discovery Center
  • Pharmaceutical Science Building B #314
  • 02-3277-6619
  • Research Interests
Research Record
  • Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis Journal of Medicinal Chemistry, 2023, v.66 no.23, 16342-16363
    SCIE Scopus dColl.
  • Meclizine, a piperazine-derivative antihistamine, binds to dimerized translationally controlled tumor protein and attenuates allergic reactions in a mouse model Biomedicine and Pharmacotherapy, 2023, v.157, 114072
    SCIE Scopus dColl.
  • Tsaokoic Acid: A New Bicyclic Nonene from the Fruits of Amomum tsao-ko with Acetylcholinesterase Inhibitory Activity Molecules (Basel, Switzerland), 2023, v.28 no.6
    SCIE Scopus dColl.
  • 2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint ACS Medicinal Chemistry Letters, 2022, v.13 no.9, 1459-1467
    SCIE Scopus dColl.
  • Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents European Journal of Medicinal Chemistry, 2022, v.244, 114837
    SCIE Scopus dColl.
  • Palladium-Catalyzed α-Arylation of Cyclic β-Dicarbonyl Compounds for the Synthesis of CaV1.3 Inhibitors ACS Omega, 2022, v.7 no.16, 14252-14263
    SCIE Scopus dColl.
  • Structure, Function, and Inhibitors of the Mitochondrial Chaperone TRAP1 Journal of Medicinal Chemistry, 2022, v.65 no.24, 16155-16172
    SCIE Scopus dColl.
  • Triphenylphosphonium conjugation to a TRAP1 inhibitor, 2-amino-6-chloro-7,9-dihydro-8H-purin-8-one increases antiproliferative activity Bioorganic Chemistry, 2022, v.126, 105856
    SCIE Scopus dColl.
  • Design and Synthesis of TRAP1 Selective Inhibitors: H-Bonding with Asn171 Residue in TRAP1 Increases Paralog Selectivity ACS MEDICINAL CHEMISTRY LETTERS, 2021, v.12 no.7, 1173-1180
    SCIE Scopus dColl.
  • Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors JOURNAL OF MEDICINAL CHEMISTRY, 2021, v.64 no.2, 958-979
    SCIE Scopus dColl.
  • Mitoquinone Inactivates Mitochondrial Chaperone TRAP1 by Blocking the Client Binding Site JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2021, v.143 no.47, 19684-19696
    SCIE Scopus dColl.
  • A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of Ca(v)1.3 L-Type Calcium Channels ACS CHEMICAL BIOLOGY, 2020, v.15 no.9, 2539-2550
    SCIE Scopus dColl.
  • Deciphering Fatty Acid Synthase Inhibition-Triggered Metabolic Flexibility in Prostate Cancer Cells through Untargeted Metabolomics Cells, 2020, v.9 no.11, 0
    SCIE Scopus dColl.
  • Development of pyrazolo[3,4-d]pyrimidine-6-amine-based TRAP1 inhibitors that demonstrate in vivo anticancer activity in mouse xenograft models Bioorganic Chemistry, 2020, v.101, 103901
    SCIE Scopus dColl.
  • Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, v.30 no.2, 126809
    SCIE Scopus dColl.
  • Physiological involvement of presynaptic L-type voltage-dependent calcium channels in GABA release of cerebellar molecular layer interneurons JOURNAL OF NEUROCHEMISTRY, 2020, v.155 no.4, 390-402
    SCIE Scopus dColl.
  • Practical direct synthesis of: N -aryl-substituted azacycles from N -alkyl protected arylamines using TiCl4and DBU Organic and Biomolecular Chemistry, 2020, v.18 no.26, 5008-5016
    SCIE Scopus dColl.
  • Casein kinase-1 gamma 1 and 3 stimulate tumor necrosis factor-induced necroptosis through RIPK3 CELL DEATH & DISEASE, 2019, v.10, 923
    SCIE Scopus dColl.
  • Metal-Free Synthesis of N-Aryl-Substituted Azacycles from Cyclic Ethers Using POCI3 JOURNAL OF ORGANIC CHEMISTRY, 2019, v.84 no.11, 6689-6696
    SCIE Scopus dColl.
  • Synthesis and evaluation of novel potent TSPO PET ligands with 2-phenylpyrazolo [1,5-a]pyrimidin-3-yl acetamide BIOORGANIC & MEDICINAL CHEMISTRY, 2019, v.27 no.18, 4069-4080
    SCIE Scopus dColl.
  • CF3-Substituted Mollugin 2-(4-Morpholinyl)-ethyl ester as a Potential Anti-inflammatory Agent with Improved Aqueous Solubility and Metabolic Stability MOLECULES, 2018, v.23 no.8, 2030
    SCIE Scopus dColl.
  • Convenient metal-free direct oxidative amidation of aldehyde using dibromoisocyanuric acid under mild conditions TETRAHEDRON LETTERS, 2018, v.59 no.39, 3541-3546
    SCIE Scopus dColl.
  • Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery MOLECULES, 2018, v.23 no.8, 1963
    SCIE Scopus dColl.
  • Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design FRONTIERS IN PHARMACOLOGY, 2018, v.9
    SCIE Scopus dColl.
  • Facile direct synthesis of unsymmetrical ureas from N-Alloc-, N-Cbz-, and N-Boc-protected amines using DABAL-Me-3 TETRAHEDRON, 2018, v.74 no.30, 4036-4046
    SCIE Scopus dColl.
  • Hypervalent Iodine-Mediated Alkene Functionalization: Oxazoline and Thiazoline Synthesis via Inter-/Intramolecular Aminohydroxylation and Thioamination ADVANCED SYNTHESIS & CATALYSIS, 2018, v.360 no.4, 779-783
    SCIE Scopus dColl.
  • Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors JOURNAL OF MEDICINAL CHEMISTRY, 2017, v.60 no.17
    SCIE Scopus dColl.
  • Electrostatic Control of Isoform Selective Inhibitor Binding in Nitric Oxide Synthase BIOCHEMISTRY, 2016, v.55 no.26, 3702-3707
    SCIE Scopus dColl.
  • Regulation of aldosterone secretion by Ca(v)1.3 SCIENTIFIC REPORTS, 2016, v.6, 24697
    SCIE Scopus dColl.
  • 2-Aminopyridines with a Truncated Side Chain To Improve Human Neuronal Nitric Oxide Synthase Inhibitory Potency and Selectivity JOURNAL OF MEDICINAL CHEMISTRY, 2015, v.58 no.14, 5548-5560
    SCIE Scopus dColl.
  • Inhibitor Bound Crystal Structures of Bacterial Nitric Oxide Synthase BIOCHEMISTRY, 2015, v.54 no.26, 4075-4082
    SCIE Scopus dColl.
  • Nitric Oxide Synthase as a Target for Methicillin-Resistant Staphylococcus aureus CHEMISTRY & BIOLOGY, 2015, v.22 no.6, 785-792
    SCIE Scopus dColl.
  • Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase JOURNAL OF MEDICINAL CHEMISTRY, 2015, v.58 no.21, 8694-8712
    SCIE Scopus dColl.
  • Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease BRAIN, 2015, v.138
    SCIE Scopus dColl.
  • Structure-Based Design of Bacterial Nitric Oxide Synthase Inhibitors JOURNAL OF MEDICINAL CHEMISTRY, 2015, v.58 no.2, 994-1004
    SCIE Scopus dColl.
  • Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain CHEMICAL SOCIETY REVIEWS, 2014, v.43 no.19, 6814-6838
    SCIE Scopus dColl.
  • The Mobility of a Conserved Tyrosine Residue Controls Isoform-Dependent Enzyme-Inhibitor Interactions in Nitric Oxide Synthases BIOCHEMISTRY, 2014, v.53 no.32, 5272-5279
    SCIE Scopus dColl.
  • [학술지논문] Development of a Fluorescence Probe for High-Throughput Screening of Allosteric Inhibitors Targeting TRAP1 JOURNAL OF MEDICINAL CHEMISTRY, 2024, v.67 no.23 , 21421-21437
    SCIE
  • [학술지논문] Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis JOURNAL OF MEDICINAL CHEMISTRY, 2023, v.66 no.23 , 16342-16363
    SCIE
  • [학술지논문] Meclizine, a piperazine-derivative antihistamine, binds to dimerized translationally controlled tumor protein and attenuates allergic reactions in a mouse model BIOMEDICINE & PHARMACOTHERAPY, 2023, v.157 no.157 , 114072-114072
    SCIE
  • [학술지논문] 2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRP alpha Checkpoint ACS MEDICINAL CHEMISTRY LETTERS, 2022, v.13 no.9 , 1459-1467
    SCIE
  • [학술지논문] Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, v.244 no.0 , 114837-114837
    SCI
  • [학술지논문] Palladium-Catalyzed alpha-Arylation of Cyclic beta-Dicarbonyl Compounds for the Synthesis of Ca(V)1.3 Inhibitors ACS OMEGA, 2022, v.7 no.16 , 14252-14263
    SCIE
  • [학술지논문] Structure, Function, and Inhibitors of the Mitochondrial Chaperone TRAP1 JOURNAL OF MEDICINAL CHEMISTRY, 2022, v.65 no.24 , 16155-16172
    SCI
  • [학술지논문] Triphenylphosphonium conjugation to a TRAP1 inhibitor, 2-amino-6--chloro-7,9-dihydro-8H-purin-8-one increases antiproliferative activity BIOORGANIC CHEMISTRY, 2022, v.126 no.126 , 105856-105856
    SCI
  • [학술지논문] Design and Synthesis of TRAP1 Selective Inhibitors: H-Bonding with Asn171 Residue in TRAP1 Increases Paralog Selectivity ACS MEDICINAL CHEMISTRY LETTERS, 2021, v.12 no.7 , 1173-1180
    SCIE
  • [학술지논문] Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors JOURNAL OF MEDICINAL CHEMISTRY, 2021, v.64 no.2 , 958-979
    SCI
  • [학술지논문] A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of Ca(v)1.3 L-Type Calcium Channels ACS CHEMICAL BIOLOGY, 2020, v.15 no.9 , 2539-2550
    SCIE
  • [학술지논문] Deciphering Fatty Acid Synthase Inhibition-Triggered Metabolic Flexibility in Prostate Cancer Cells through Untargeted Metabolomics CELLS, 2020, v.9 no.11 , 2447-2447
    SCIE
  • [학술지논문] Development of pyrazolo[3,4-d]pyrimidine-6-amine-based TRAP1 inhibitors that demonstrate in vivo anticancer activity in mouse xenograft models BIOORGANIC CHEMISTRY, 2020, v.101 no.0 , 103901-103901
    SCI
  • [학술지논문] Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, v.30 no.2 , 126809-126809
    SCI
  • [학술지논문] Physiological involvement of presynaptic L-type voltage-dependent calcium channels in GABA release of cerebellar molecular layer interneurons JOURNAL OF NEUROCHEMISTRY, 2020, v.155 no.4 , 390-402
    SCI
  • [학술지논문] Practical direct synthesis of N-aryl-substituted azacycles from N-alkyl protected arylamines using TiCl4 and DBU ORGANIC & BIOMOLECULAR CHEMISTRY, 2020, v.18 no.26 , 5008-5016
    SCI
Read More
Courses

  • 2025-1st

    • Honors research

    • Pharmaceutical Organic Chemistry Ⅰ

      • Subject No 38931Class No 01
      • 2Year ( 3Credit , 3Hour) Mon 5~5 (PHM-A100-1) , Thu 4~4 (POSCO555)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Organic Chemistry Ⅰ

      • Subject No 38931Class No 02
      • 2Year ( 3Credit , 3Hour) Mon 4~4 (PHM-A100-1) , Thu 5~5 (POSCO359)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Synthesis Ⅰ

      • Subject No 38947Class No 01
      • 3Year ( 3Credit , 3Hour) Tue 5~5 (POSCO359) , Fri 4~4 (PHM-A104)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Synthesis Ⅰ

      • Subject No 38947Class No 02
      • 3Year ( 3Credit , 3Hour) Mon 2~2 (PHM-A100-1) , Fri 3~3 (PHM-A104)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Experiment Ⅰ

      • Subject No 38963Class No 01
      • 3Year ( 2Credit , 3Hour) Mon 6~9 (PHM-A309)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Experiment Ⅰ

      • Subject No 38963Class No 02
      • 3Year ( 2Credit , 3Hour) Tue 6~9 (PHM-A309)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Organic Chemistry Ⅰ

      • Subject No 39036Class No 01
      • 2Year ( 3Credit , 3Hour) Tue 3~3 (PHM-A100-1) , Thu 2~2 (PHM-A104)
      • Major Requisite
        • Syllabus(File)

    • Introduction to Pharmaceutical Research

      • Subject No 39045Class No 01
      • 2Year ( 1.5Credit , 1.5Hour) Thu 6~6 (PHM-A104)
        • Syllabus(File)

    • Pharmaceutical Synthesis Ⅰ

      • Subject No 39052Class No 01
      • 3Year ( 3Credit , 3Hour) Tue 2~2 (PHM-A100-1) , Thu 3~3 (POSCO359)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Experiment Ⅰ

      • Subject No 39068Class No 01
      • 3Year ( 2Credit , 3Hour) Wed 6~9 (PHM-A309)
      • Major Requisite
        • Syllabus(File)

    • Advanced Medicinal Chemistry Ⅰ

      • Subject No G16861Class No 01
      • Year ( 3Credit , 3Hour) Wed 5~6 (PHM-)
        • Syllabus(File)

  • 2023-2nd

  • 2023-1st

  • 2022-2nd

    • Pharmaceutical Synthesis Ⅲ

      • Subject No 33948Class No 01
      • 4Year ( 1.5Credit , 1.5Hour) Tue 4~4 (PHM-A100-1)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Synthesis Ⅲ

      • Subject No 33948Class No 02
      • 4Year ( 1.5Credit , 1.5Hour) Tue 3~3 (PHM-A100-1)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Synthesis Ⅲ

      • Subject No 33948Class No 03
      • 4Year ( 1.5Credit , 1.5Hour) Thu 5~5 (PHM-A100-1)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Synthesis Ⅲ

      • Subject No 33948Class No 04
      • 4Year ( 1.5Credit , 1.5Hour) Thu 5~5 (PHM-A100-1)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 01
      • 4Year ( 1.5Credit , 3Hour) Mon 6~7 (PHM-A309)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 02
      • 4Year ( 1.5Credit , 3Hour) Tue 6~7 (PHM-A309)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 03
      • 4Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A309)
      • Major Requisite
        • Syllabus(File)

    • Advanced Pharmacy Practice and Research I

      • Subject No 37154Class No 01
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
        • Syllabus(File)

    • Honors research

    • Advanced Medicinal Chemistry II

      • Subject No G16905Class No 01
      • Year ( 3Credit , 3Hour) Wed 2~3 (PHM-)
        • Syllabus(File)

    • Understanding and application of Bioinformatics and Chemoinformatics

      • Subject No G18091Class No 01
      • Year ( 3Credit , 3Hour) Mon 2~3 (PHM-)
        • Syllabus(File)

  • 2022-1st

    • Pharmaceutical Chemistry

      • Subject No 22576Class No 01
      • 3Year ( 3Credit , 3Hour) Tue 2~2 , Thu 3~3
        • Syllabus(File)

    • Pharmaceutical Chemistry

      • Subject No 22576Class No 02
      • 3Year ( 3Credit , 3Hour) Tue 3~3 , Thu 4~4
        • Syllabus(File)

    • Pharmaceutical Synthesis Ⅱ

      • Subject No 33947Class No 01
      • 4Year ( 3Credit , 3Hour) Tue 5~5 (PHM-A400) , Wed 3~3 (PHM-A400)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Synthesis Ⅱ

      • Subject No 33947Class No 02
      • 4Year ( 3Credit , 3Hour) Mon 4~4 (PHM-A400) , Wed 4~4 (PHM-A400)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Synthesis Ⅱ

      • Subject No 33947Class No 03
      • 4Year ( 3Credit , 3Hour) Mon 3~3 (PHM-A100-1) , Thu 6~6 (PHM-A400)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Synthesis Ⅱ

      • Subject No 33947Class No 04
      • 4Year ( 3Credit , 3Hour) Mon 3~3 (PHM-A100-1) , Thu 6~6 (PHM-A400)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 01
      • 4Year ( 1.5Credit , 3Hour) Tue 6~7 (PHM-A309)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 02
      • 4Year ( 1.5Credit , 3Hour) Mon 6~7 (PHM-A309)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 03
      • 4Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A309)
      • Major Requisite
        • Syllabus(File)

    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 04
      • 4Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A309)
      • Major Requisite
        • Syllabus(File)

    • Advanced Medicinal Chemistry I

      • Subject No G16861Class No 01
      • Year ( 3Credit , 3Hour) Fri 5~6 (PHM-)
        • Syllabus(File)
Read More
Academic Background

Purdue University Ph.D.(Chemistry)